Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gap junctions give rhythm

Wyeth's Cordarone amiodarone is the world's leading anti-arrhythmia drug, yet it sold only $283 million last year after going generic in the fourth quarter. Side effects have limited sales of all anti-arrhythmics, and although WYE and others have tried to find better compounds, none have yet succeeded. In fact, WYE has nothing in the clinic to replace

Read the full 574 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers